Brief: Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
07/05/2026 13:09
May 7 (Reuters) - Atara Biotherapeutics Inc ATRA.O: ATARA BIOTHERAPEUTICS PROVIDES REGULATORY UPDATE ON TABELECLEUCEL ATARA BIOTHERAPEUTICS INC - FDA AGREES SINGLE ARM STUDY MAY SUPPORT FUTURE TAB-CEL MARKETING APPLICATION ATARA BIOTHERAPEUTICS INC - EXPECTS FURTHER TAB-CEL REGULATORY UPDATE IN THIRD QUARTER Source text: ID:nBw44Sgxca Further company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing